News and Announcements
Riccardo Canevari of Radiopharm Theranostics (ASX:RAD)
- Published December 06, 2022 6:49AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Radiopharm Theranostics (ASX:RAD) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, from some of the world’s leading universities and institutes.
Watch this interview with CEO Riccardo Canevari as he discusses how they approach oncology with their unique processes.
Executive Interviews
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Navigating the Future of Capital: Insights from MENA’s VC and PE Leaders
The venture capital and private equity landscape in the MENA (Middle East and North Africa) region is experiencing dynamic shifts, driven by rapid technological advancements, evolving investor demands, and unique regional priorities. A recent panel featuring prominent figures in the MENA investment scene offered a glimpse into these transformations, highlighting key trends for founders and […]
Web3’s Maturing Landscape and Trillion-Dollar Opportunities
The narrative around Web3 is rapidly evolving. While many still associate it primarily with the speculative highs and lows of cryptocurrencies, the reality is a rapidly maturing ecosystem brimming with genuine innovation and significant investment potential. As Steve Torso, Co-founder & Managing Director of Wholesale Investor & CapitalHQ, aptly puts it, “It’s only got 8% […]
Backed By Leading Investment Groups and Family Offices
